Industries > Pharma > World Vaccines Industry and Market 2015-2025

World Vaccines Industry and Market 2015-2025

PUBLISHED: 03 February 2015
PAGES: 169
PRODUCT CODE: PHA0026
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0026 Categories: ,

Vaccines and their technology – your guide to developments, opportunities and revenues
See what the future holds for vaccines. Visiongain’s new report lets you assess forecasted sales at overall world market, submarket, product and national level to 2025.

Make sure you understand the trends, R&D, opportunities and prospects in human medicine. That way you can help your research, analysis and decisions. For those technologies, you will discover in our study what’s likely to happen. And find what gains are possible. 

Vaccines still hold great technological, medical and commercial potential. So please read on to explore the industry and hear what its future market could be worth.

Forecasts from 2015 to 2025 and other analyses showing you commercial prospects
Besides revenue forecasting to 2025, our new work gives you historical data, recent results, growth rates and market shares. There you will find business outlooks and developments (R&D). 

You will also get 50 tables, 49 charts and two interviews, with other opinion, including our discussions with GSK and BiondVax Pharmaceuticals.

Gains through understanding the vaccines sector – find advantages for your work
Leaders hold knowledge. So hear what’s happening for development, production and sales of those preventative medicines. From 2015 onwards you will see where the needs and prospects arr.

And avoid struggling to gain business information. Instead use our predictions for vaccination to expand your business and help your influence. That way you will benefit your authority and stay ahead. 

Discover how you and your organisation can gain. The following sections reveal what you will get in our new investigation.

Revenues for the world vaccines market and submarkets
What’s the industry's potential? What are the secrets of its progress? Discover in our report overall world revenues to 2025. Also you will find individual forecasts for the main submarkets at world level:

•    Paediatric vaccines
•    Adult vaccines.

How will sales rise? See which product classes can generate most revenue. There you can assess the prospects for commercial expansion. Discover now the money-earning potential.

Explore the market for vaccinations by brand too.

Forecasts and discussions for leading marketed products
How will the leading brands perform to 2025 at world level? Our work shows you the 10 individual revenue forecasts to 2025 for top products: 

•    Prevnar group
•    Gardasil
•    PENTAct-HIB
•    Pediarix
•    Varivax/M-M-R II/ProQuad.

And also for these agents: 

•    Fluzone/Vaxigrip
•    Hepatitis group, GSK
•    Zostavax
•    Pneumovax-23
•    RotaTeq.

There you can assess the potentials, seeing activities, results and outlooks. You will discover what’s happening, understanding trends, competition and sales prospects. You will be able to assess the future including the prospects for newer agents.

Newer vaccines and products in development – how will leading candidates perform?
Also see how newer agents, especially those in development and awaiting launch, can perform.  For these 11 medicines, you can see revenues to 2025:

•    Zoster and Malaria vaccines (GSK)
•    9-valent HPV agents (Merck)
•    Hexavalent paediatric vaccines (Sanofi)
•    Dengue fever products (Sanofi)
•    Trumenba vaccines (Pfizer).

And you will get forecasts for these treatments:

•    C. difficile and S. aureus vaccines (Pfizer)
•    Ebola vaccines (Johnson & Johnson)
•    Dengue fever vaccines (Takeda)
•    Universal influenza vaccines (BiondVax).

There you can assess the future of the industry’s developments, finding sales gains possible. 

Our study also divides its overarching world forecast into geographical regions.

Healthcare in national markets – what outlooks for sales of those medicines?
Progress worldwide in vaccines and healthcare will expand vaccination. You will hear about the best revenue prospects for those preventative medicines, getting a feel for the national prospects.

Our analyses show you individual revenue forecasts to 2025 for 11 national markets:

•    United States (US)
•    Japan
•    European Union (grouped forecast)
•    Germany, France, United Kingdom (UK), Italy and Spain (EU5 countries)
•    Brazil, Russia, India and China (BRIC group).

There you can assess the developed and developing countries for revenues and potential sales growth. Our work explains the effects of existing and future prophylactic medicines.

Research and development – explore trends, possibilities and innovations
Our study discusses R&D for immune system modifiers, finding possibilities for technological and commercial advances.

In particular, our report discusses these medical technologies:

•    Influenza vaccines
•    Prophylactic treatments, including those for meningitis, pneumonia, TB, diphtheria, pertussis, tetanus and rotaviruses
•    Protectors against Dengue virus
•    Vaccines for HIV, malaria and bacteria
•    Prophylaxis in oncology – cancer vaccines – including agents for prostate, pancreatic and lung cancers.

Developments in those immunological treatments hold strength, variety and promise. See what’s possible there for large pharmaceutical companies and biopharma specialists. 

Our study explains progress in human prophylaxis, discussing issues to help your work. 

Events affecting developers, producers and sellers of vaccines
Our report explains the forces affecting the industry and market from 2015, including these issues: 

•    Importance of those products to the pharmaceutical industry
•    Immunisation needs and practices in the US
•    Medical demands vying with budgetary restraints in Europe
•    Rising need in emerging countries and under-developed regions
•    Delivery systems, adjuvants and other innovations.

There you can explore the political, economic, social and technological questions, investigating the outlook for business. Examine the forces stimulating and restraining the industry and market. 

You will discover what the present and future hold for vaccines.

Companies and overall 2019 market value – what revenues are possible?
What happens next? Our report predicts the overall world market for vaccines will reach $56.38bn worldwide in 2019, with strong further expansion to 2025. 

Find how high the revenues can go. Discover in our work what’s possible for prophylactic medicine and see which companies hold the greatest potential. 

In particular, you can explore these organisations:

•    GlaxoSmithKline (GSK)
•    Sanofi
•    Pfizer
•    Johnson & Johnson
•    AstraZeneca
•    Takeda
•    Merck & Co.

From 2015 to 2025 vaccines will benefit patients, payers and companies. Our analysis predicts technological and commercial advances there. Stay ahead by using our work.

Data found nowhere else – explore vaccine development, production and sales 
In particular, our new investigation gives you these advantages for your research, analyses and decisions:

•    Revenues to 2025 for vaccines at world level and for two main submarkets – assess prospects for investments, marketing and sales

•    Predictions for 21 products to 2025 – discover the revenue potentials of leading marketed vaccines and agents in development, awaiting launch

•    Forecasts to 2025 for 11 national markets in the Americas, Europe and Asia – investigate the developed and developing countries for potential revenues
 
•    Prospects for established competitors, rising companies and new entrants – explore the products, R&D, opinions from interviews and outlooks for success.

World Vaccines Industry and Market 2015-2025 provides independent research and analysis. You will receive competitive intelligence found only in our work, finding where the most promising prospects exist. Explore the industry’s progress and commercial possibilities.

With our report, by in-house UK-based analysts, you’re less likely to miss knowledge and opportunity. Also you will find how you could save time and gain more recognition and credit for insight.

Trying our study now lets you discover the trends, predictions and sales opportunities
Our investigation is for everyone analysing preventative medicines and related biotechnology. There you can discover predictions and discussions for vaccines. Avoid missing out. Instead please purchase our new report now.

Visiongain is a trading partner with the US Federal Government

CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for World Vaccines Industry and Market 2015-2025


Download sample pages

Complete the form below to download your free sample pages for World Vaccines Industry and Market 2015-2025


Latest Pharma news

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

READ

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

READ

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

READ

Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2021-2031

Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.

12 July 2021

READ

Categories